patients cohort

Aliases

human patients, participants, patient, recurrent unipolar depression patients, subjects

No related entities found.

Mentioned in (79)

Papers in which this entity is mentioned.

• Reliability of LLMs as medical assistants for the general public: a randomized preregistered study. (2026)
• Rapid brain tumor classification from sparse epigenomic data. (2025)
• Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma. (2024)
• Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach. (2024)
• Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. (2024)
• The landscape of drug sensitivity and resistance in sarcoma. (2024)
• Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. (2024)
• A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges. (2024)
• A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns. (2023)
• Human 3D brain organoids: steering the demolecularization of brain and neurological diseases. (2023)
• Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors. (2023)
• Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. (2023)
• Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. (2023)
• PheNominal: an EHR-integrated web application for structured deep phenotyping at the point of care. (2022)
• Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. (2022)
• Genome-wide mutational signatures in low-coverage whole genome sequencing of cell-free DNA. (2022)
• Epigenetic analysis of cell-free DNA by fragmentomic profiling. (2022)
• Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. (2022)
• Single-cell genomic variation induced by mutational processes in cancer. (2022)
• Inferring gene expression from cell-free DNA fragmentation profiles. (2022)
• Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. (2022)
• Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. (2022)
• Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. (2022)
• Med-BERT: pretrained contextualized embeddings on large-scale structured electronic health records for disease prediction. (2021)
• Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. (2021)
• Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. (2021)
• A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. (2021)
• Detection and characterization of lung cancer using cell-free DNA fragmentomes. (2021)
• Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. (2021)
• Immuno-genomic landscape of osteosarcoma. (2020)
• Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. (2020)
• AmpliconReconstructor integrates NGS and optical mapping to resolve the complex structures of focal amplifications. (2020)
• Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. (2020)
• Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. (2019)
• Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. (2019)
• The mutational footprints of cancer therapies. (2019)
• Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. (2019)
• Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. (2019)
• The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. (2019)
• Genome-Informed Targeted Therapy for Osteosarcoma. (2019)
• Pan-cancer whole-genome analyses of metastatic solid tumours. (2019)
• Genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. (2018)
• Genome doubling shapes the evolution and prognosis of advanced cancers. (2018)
• The Immune Landscape of Cancer. (2018)
• Tumor fraction in cell-free DNA as a biomarker in prostate cancer. (2018)
• Copy number signatures and mutational processes in ovarian carcinoma. (2018)
• OncoKB: A Precision Oncology Knowledge Base. (2017)
• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. (2017)
• Integrative clustering of multi-level 'omic data based on non-negative matrix factorization algorithm. (2017)
• Patient-derived xenografts undergo mouse-specific tumor evolution. (2017)
• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. (2017)
• Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. (2017)
• Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. (2017)
• Integrated digital error suppression for improved detection of circulating tumor DNA. (2016)
• Fragment Length of Circulating Tumor DNA. (2016)
• Landscape of somatic mutations in 560 breast cancer whole-genome sequences. (2016)
• The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. (2016)
• Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. (2016)
• Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. (2016)
• Development and clinical application of an integrative genomic approach to personalized cancer therapy. (2016)
• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015)
• Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. (2015)
• Clinical exome performance for reporting secondary genetic findings. (2015)
• The human gene damage index as a gene-level approach to prioritizing exome variants. (2015)
• Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. (2015)
• Systematic pan-cancer analysis of tumour purity. (2015)
• Unraveling the clonal hierarchy of somatic genomic aberrations. (2014)
• Prenatal alcohol exposure reduces magnetic susceptibility contrast and anisotropy in the white matter of mouse brains. (2014)
• Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. (2014)
• VariantDB: a flexible annotation and filtering portal for next generation sequencing data. (2014)
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. (2014)
• DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. (2013)
• ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. (2013)
• Clinical whole-exome sequencing for the diagnosis of mendelian disorders. (2013)
• Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. (2013)
• Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. (2013)
• Patient-derived tumour xenografts as models for oncology drug development. (2012)
• MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. (2008)
• PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. (2007)

Merged raw entities (3)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.